Improving Local Tumor Control by Combining Vascular Targeting Drugs, Mild Hyperthermia and Radiation
Overview
Authors
Affiliations
Improvement in local control in a foot-implanted (200 mm3) C3H mouse mammary carcinoma by combining vascular targeting drugs, mild hyperthermia and radiation was investigated. The vascular targeting drug was flavone acetic acid (FAA; 150 mg/kg) intraperitoneally injected either 3 h before local tumor water-bath heating or 1 h after local tumor irradiation. For untreated tumors, the average (+/- 1 S.E.) tumor growth time (TGT; time to reach 5 x treatment volume) was 7.1 days (+/- 0.4). This was increased to 9.2 days (+/- 0.7) by using FAA. Heating also increased TGT, the effect being temperature and time dependent, and this heat response was further increased by FAA. The radiation dose (+/- 95% confidence interval) to control 50% of tumors (TCD50) 90 days after irradiation was 52 Gy (50-55) for radiation alone. This was decreased to 42 Gy (39-45) by FAA, 47 Gy (45-50) by heating (41.5 degrees C; 60 min) 4 h after irradiation, and to 28 Gy (22-35) by combining FAA and heat. Thus, vascular targeting drugs can improve the efficacy of mild hyperthermia and radiation.
Rapid, Reversible Release from Thermosensitive Liposomes Triggered by Near-Infra-Red Light.
Forbes N, Pallaoro A, Reich N, Zasadzinski J Part Part Syst Charact. 2017; 31(11):1158-1167.
PMID: 29167602 PMC: 5695930. DOI: 10.1002/ppsc.201400035.
Radiotherapy in combination with vascular-targeted therapies.
Ciric E, Sersa G Radiol Oncol. 2012; 44(2):67-78.
PMID: 22933894 PMC: 3423684. DOI: 10.2478/v10019-010-0025-9.
Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors.
Griffin R, Williams B, Koonce N, Bischof J, Song C, Asur R J Oncol. 2012; 2012:934918.
PMID: 22272199 PMC: 3261488. DOI: 10.1155/2012/934918.
Ranjan A, Jacobs G, Woods D, Negussie A, Partanen A, Yarmolenko P J Control Release. 2012; 158(3):487-94.
PMID: 22210162 PMC: 3319290. DOI: 10.1016/j.jconrel.2011.12.011.
The Kadota Fund International Forum 2004--clinical group consensus.
van der Zee J, Vujaskovic Z, Kondo M, Sugahara T Int J Hyperthermia. 2008; 24(2):111-22.
PMID: 18283588 PMC: 2759185. DOI: 10.1080/02656730801895058.